Results 61 to 70 of about 2,752 (194)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease

International Journal of COPD, 2012
Osamu Hataji,1 Masahiro Naito,1 Kentaro Ito,1 Fumiaki Watanabe,1 Esteban C Gabazza,2 Osamu Taguchi31Respiratory Center, Matsusaka Municipal Hospital, Tonomachi, 2Department of Immunology, 3Department of Pulmonary and Critical Care Medicine, Mie ...
Hataji O, Naito M, Ito K, Watanabe F, Gabazza EC, Taguchi O   +5 more
doaj  

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

Respiratory Research, 2011
Background Indacaterol is a once-daily long-acting inhaled β2-agonist indicated for maintenance treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD).
Lawrence David, Kramer Benjamin, Looby Michael, Renard Didier, Morris David, Stanski Donald R   +5 more
doaj   +1 more source

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort

International Journal of COPD, 2013
Mukesh P SinghHorsefair Practice Group, Sandy Lane Health Centre, Rugeley, UKBackground: Once-daily long-acting β2-agonists (LABAs) are an important treatment option, either alone or in combination with other inhaled long-acting bronchodilators in ...
Singh MP
doaj  

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol

International Journal of COPD, 2014
Neil S Roskell,1 Antonio Anzueto,2 Alan Hamilton,3 Bernd Disse,4 Karin Becker5 1Statistics, Bresmed Health Solutions Ltd, Sheffield, UK; 2School of Medicine, University of Texas Health Science Center, San Antonio, TX, USA; 3Medical Department, Boehringer
Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K   +4 more
doaj  

The translational value of ligand‐receptor binding kinetics in drug discovery

British Journal of Pharmacology, Volume 181, Issue 21, Page 4117-4129, November 2024.
Abstract The translation of in vitro potency of a candidate drug, as determined by traditional pharmacology metrics (such as EC50/IC50 and KD/Ki values), to in vivo efficacy and safety is challenging. Residence time, which represents the duration of drug‐target interaction, can be part of a more comprehensive understanding of the dynamic nature of drug‐
Hongli Liu, Haoran Zhang, Adriaan P. IJzerman, Dong Guo   +3 more
wiley   +1 more source

NEW FIXED COMBINATION OF LONG-ACTING ANTICHOLINERGIC GLYCOPYRRONIUM BROMIDE AND β2-AGONIST OF INDACATEROL: PROSPECTS OF COBD THERAPY

Медицинский совет, 2016
The therapy by fixed combinations, LABA/LAACD on the basis of indacaterol and glycopyrronium bromide is characterized by a high clinical efficacy compared to monocomponents of the product, tiotropium, and a fixed combination of LABA/iCGS.
S. N. AVDEEV
doaj   +1 more source

Comparison of Free‐Breathing 3D Phase‐Resolved Functional Lung (PREFUL) MRI With Dynamic 19F Ventilation MRI in Patients With Obstructive Lung Disease and Healthy Volunteers

Journal of Magnetic Resonance Imaging, Volume 60, Issue 4, Page 1416-1431, October 2024.
Background Non‐contrast‐enhanced 1H magnetic resonance imaging (MRI) with full lung coverage shows promise for assessment of regional lung ventilation but a comparison with direct ventilation measurement using 19F MRI is lacking. Purpose To compare ventilation parameters calculated using 3D phase‐resolved functional lung (PREFUL) MRI with 19F MRI ...
Filip Klimeš, Arnd J. Obert, Julienne Scheller, Marius M. Wernz, Andreas Voskrebenzev, Marcel Gutberlet, Robert Grimm, Hendrik Suhling, Robin A. Müller, Till F. Kaireit, Julian Glandorf, Tawfik Moher Alsady, Frank Wacker, Jens Vogel‐Claussen   +13 more
wiley   +1 more source

The role of indacaterol for chronic obstructive pulmonary disease (COPD)

, 2013
Indacaterol is the first long-acting β2-agonist (LABAs) approved for the treatment of chronic obstructive pulmonary disease (COPD) that allows for once-daily (OD) administration. It is rapidly acting, with an onset of action in 5 minutes, like salbutamol
CAZZOLA, MARIO, Cazzola, M, Stirpe, E, STIRPE, EMANUELE, Bardaro, F   +4 more
core   +1 more source

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

International Journal of COPD, 2010
Beatrix Balint1, Henrik Watz2, Carolynn Amos3, Roger Owen3, Mark Higgins3, Benjamin Kramer4, On behalf of the INSURE* Study Investigators1Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórh& ...
Beatrix Balint, Henrik Watz, Carolynn Amos, et al   +3 more
doaj  

Adverse events of Indacaterol vs. Tiotropium monotherapy.

, 2015
COPD = Chronic obstructive pulmonary disease.*INTENSITY study was not included in the analysis of serious cardiovascular event.†Serous cardiovascular events of INHANCE study were analyzed with both indacaterol 150ug and 300ug group.‡INVIGORATE study with
Yeon-Mok Oh (709680), Yong Bum Park (709682), Hye Yun Park (404092), Jung Soo Kim (311873), Seong Yong Lim (709679), Kwang Ha Yoo (709681), Seung Soo Sheen (709683), Ji Ye Jung (709685), Min-Ji Kim (280727), Jinkyeong Park (709678), K. C. Carriere (709684)   +10 more
core   +1 more source